IMR Press / FBS / Volume 4 / Issue 3 / DOI: 10.2741/S309

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Prophylactic vaccines for prevention of prostate cancer
Show Less
1 Reproductive Immunology and Molecular Biology Lab, Department of Obstetrics and Gynecology, The West Virginia University, School of Medicine, Health Sciences Center, Morgantown, WV 26506-9186

*Author to whom correspondence should be addressed.

Academic Editor: Rajesh K. Naz

Front. Biosci. (Schol Ed) 2012, 4(3), 932–940;
Published: 1 January 2012
(This article belongs to the Special Issue Male reproductive medicine)

Prostate cancer is the most prevalent cancer and the second leading cause of cancer death in men. There are various modalities for treatment of prostate cancer. Immunotherapy with several vaccines and antibodies has also been successfully used with positive clinical outcome in prostate cancer patients. The majority of these vaccines are palliative and have been employed when a person is already diagnosed with prostate cancer. The aim of this article is to review various vaccines that have been examined for immunoprophylactic prevention of initiation/development/metastasis of prostate cancer. The Pubmed database and Google Scholar search identified 26 articles on various vaccines that have been investigated for prophylactic prevention of cancer development. These vaccines targeted prostate-specific/restricted antigens (PSA/PSMA/PSCA), oncoproteins (GRP/MUC family, erbB2/HER-2/neu), whole tumor cell antigens, prostate regulating hormones (GnRH/testosterone), and various cytokines and immune modulators. The data indicates that the development of immunoprophylactic vaccines for prostate cancer is an exciting proposition, which can translate into a viable reality for clinical application in humans.

Back to top